UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy

Kidney international reports, 2023-12, Vol.8 (12), p.2754-2764

2023

Volltextzugriff (PDF)

P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI‐C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)

HemaSphere, 2023-08, Vol.7 (S3), p.e17022e8-n/a

2023

Volltextzugriff (PDF)

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

Blood, 2023-11, Vol.142 (Supplement 1), p.4096-4096

2023

Volltextzugriff (PDF)

3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSING OF IPTACOPAN

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

Exposure-Response Relationships between the Factor B Inhibitor Iptacopan and Complement Biomarkers in Healthy Volunteers and Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G) or IgA Nephropathy (IgAN)

Blood, 2023-11, Vol.142 (Supplement 1), p.5640-5640

2023

Volltextzugriff (PDF)

4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

Exposure-Response Relationships between the Complement Factor B Inhibitor Iptacopan and Lactate Dehydrogenase (LDH) and Hemoglobin (Hb) in Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Blood, 2023-11, Vol.142 (Supplement 1), p.5643-5643

2023

Volltextzugriff (PDF)

WCN24-555 PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN

Kidney international reports, 2024-04, Vol.9 (4), p.S111-S112

2024

Volltextzugriff (PDF)

A Multicohort Biomarker Study in Patients with Advanced CKD on Peritoneal Dialysis or Hemodialysis and in Healthy Volunteers Investigating Inflammatory Markers: SA-PO441

Journal of the American Society of Nephrology, 2024-10, Vol.35 (10S)

2024

Volltextzugriff (PDF)

MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE

Nephrology, dialysis, transplantation, 2020-06, Vol.35 (Supplement_3)

2020

Volltextzugriff (PDF)

12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Blood, 2021-11, Vol.138 (Supplement 1), p.2173-2173

2021

Volltextzugriff (PDF)

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.5803-5804

2022

Volltextzugriff (PDF)

12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G: TH-PO505

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.190-190

2022

Volltextzugriff (PDF)

Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy: FR-OR59

Journal of the American Society of Nephrology, 2022-11, Vol.33 (11S), p.33-34

2022

Volltextzugriff (PDF)

FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY

Nephrology, dialysis, transplantation, 2021-05, Vol.36 (Supplement_1)

2021

Volltextzugriff (PDF)

WCN24-550 SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCREASES PLASMA COMPLEMENT Bb LEVELS

Kidney international reports, 2024-04, Vol.9 (4), p.S111-S111

2024

Volltextzugriff (PDF)

Iptacopan, a Novel Oral Complement Factor B (FB) Inhibitor, Significantly Reduces Proteinuria and C3 Deposit Scores in Native and Transplanted Kidneys C3 Glomerulopathy (C3G) Patients: PO2536

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.B8-B8

2021

Volltextzugriff (PDF)

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study

Blood advances, 2022-08, Vol.6 (15), p.4450-4460

2022

Volltextzugriff (PDF)

Long-term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome

Pediatrics (Evanston), 2018-01, Vol.141 (1_MeetingAbstract), p.270-270

2018

Volltextzugriff (PDF)

Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial

Journal of Transplantation, 2011-01, Vol.2011 (2011), p.233-239

2011

Volltextzugriff (PDF)

Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy

Kidney international reports, 2024-10

2024

Volltextzugriff (PDF)

The role of everolimus in liver transplantation

Clinical and experimental gastroenterology, 2014-01, Vol.7 (default), p.329-343

2014

Volltextzugriff (PDF)

LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy: SU-OR39

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.55-55

2020

Volltextzugriff (PDF)

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation: Renal function, efficacy and safety with everolimus + tacrolimus minimization

Transplant international, 2012-05, Vol.25 (5), p.592-602

2012

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(56)

Publikationsform

Sprache

Englisch
(38)
Deutsch
(24)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy

P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI‐C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

3278 HUMAN PHARMACOKINETICS OF MULTIPLE, STEADY-STATE DOSING OF IPTACOPAN

4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS

Exposure-Response Relationships between the Factor B Inhibitor Iptacopan and Complement Biomarkers in Healthy Volunteers and Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G) or IgA Nephropathy (IgAN)

4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS

Exposure-Response Relationships between the Complement Factor B Inhibitor Iptacopan and Lactate Dehydrogenase (LDH) and Hemoglobin (Hb) in Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH)

WCN24-555 PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN

A Multicohort Biomarker Study in Patients with Advanced CKD on Peritoneal Dialysis or Hemodialysis and in Healthy Volunteers Investigating Inflammatory Markers: SA-PO441

MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE

12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G: TH-PO505

Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy: FR-OR59

FC 036IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY

WCN24-550 SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCREASES PLASMA COMPLEMENT Bb LEVELS

Iptacopan, a Novel Oral Complement Factor B (FB) Inhibitor, Significantly Reduces Proteinuria and C3 Deposit Scores in Native and Transplanted Kidneys C3 Glomerulopathy (C3G) Patients: PO2536

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study

Long-term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome

Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial

Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy

The role of everolimus in liver transplantation

LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy: SU-OR39

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation: Renal function, efficacy and safety with everolimus + tacrolimus minimization

Aktive Filter

Suchergebnisse filtern